The World Bank Working for a World Free of Poverty Microdata Library
  • Data Catalog
  • About
  • Collections
  • Citations
  • Terms of use
  • Login
    Login
    Home / Central Data Catalog / IMPACT_EVALUATION / BFA_2017_HRBFIE-FEL_V01_M / variable [F9]
impact_evaluation

Results-Based Financing Impact Evaluation Health Facility 2017, Endline Survey

Burkina Faso, 2017
Get Microdata
Reference ID
BFA_2017_HRBFIE-FEL_v01_M
DOI
https://doi.org/10.48529/01gp-gm52
Producer(s)
Manuela de Allegri, Herve Hien, Paul Jacob Robyn
Collection(s)
Impact Evaluation Surveys Fragility, Conflict and Violence
Metadata
Documentation in PDF DDI/XML JSON
Created on
Aug 27, 2019
Last modified
Oct 01, 2019
Page views
117008
Downloads
2014
  • Study Description
  • Data Description
  • Documentation
  • Get Microdata
  • Related datasets
  • Data files
  • f1_jul19
  • f1p_jul19
  • f1u_jul19
  • f2_jul19
  • f3_jul19
  • f4_jul19
  • f5_jul19
  • f6_jul19
  • f7_jul19

F7_219_M (f7_219_1)

Data file: f7_jul19

Overview

Valid: 224
Invalid: 0
Type: Discrete
Start: 510
End: 534
Width: 25
Range: -
Format: character

Questions and instructions

Categories
Value Category Cases
0 1
0.4%
00 21
9.4%
1 1
0.4%
3 2
0.9%
99 1
0.4%
A 1
0.4%
AMOXI 1
0.4%
AMOXI GELLULE 1
0.4%
AMOXI GELLULE 500MG 1
0.4%
ART LUM 1
0.4%
Albendazole 1
0.4%
Amoxi 500mg 1
0.4%
Amoxicilline 6
2.7%
Amoxicilline gellule 1
0.4%
Amoxycilline 1
0.4%
Artemether 2
0.9%
Artemether-lumefantrine 1
0.4%
AtL 1
0.4%
Butyl cp 1
0.4%
CEFTIAXONE 1
0.4%
COTRI 480MG 1
0.4%
COTRI CP 480MG 1
0.4%
Ciprofloxacine cp 1
0.4%
Cotri 480mg 1
0.4%
DEPOT PROVERA 1
0.4%
DICLOFENAC 1
0.4%
Depo Provera 1
0.4%
Depo provera 2
0.9%
Depoprovera 1
0.4%
Hydroxide 1
0.4%
Hydroxide d'aluminium 1
0.4%
Injectable SP 1
0.4%
Intranule 1
0.4%
Jadelle 4
1.8%
Lumartem cp 1
0.4%
MEO 2
0.9%
METO CP 1
0.4%
METRONIDAZOLE 1
0.4%
Metronidazole 250mg 1
0.4%
Norplant 2
0.9%
Nystatine 1
0.4%
Nystatine ovule 1
0.4%
PHLORO CP 1
0.4%
PHLOROGLUCINOL 1
0.4%
Paracetamol 5
2.2%
Paracetamol cp 2
0.9%
Phloroglucinol 1
0.4%
Phloroglucinol cp 1
0.4%
Ploroglucinol 1
0.4%
QUININE 300MG 1
0.4%
Quinine 3
1.3%
Quinine 300mg 3
1.3%
VAT 1
0.4%
VAT 1 DOSE 1
0.4%
VITA C 1
0.4%
Vitamine A 1
0.4%
albendazole 1
0.4%
albendazolz 1
0.4%
amixiciline 1
0.4%
amoxi 2
0.9%
amoxi gellule 1
0.4%
amoxiciline 4
1.8%
amoxicilline 2
0.9%
amoxicilline comp 2
0.9%
amoxicilline gel 1
0.4%
amoxicilline gel 500mg 1
0.4%
amoxicilline gelules 1
0.4%
amoxicilline sirop 1
0.4%
amoxycilline 1
0.4%
art lum 1
0.4%
artemether 1
0.4%
artemether lumartem 1
0.4%
artesunate amodiaquine 2
0.9%
artesunate cp 1
0.4%
artesunate et amodiaquine 1
0.4%
arthemeter 1
0.4%
arthemeter lumef antrine 1
0.4%
atemeter lumefantrine 1
0.4%
butul comprime 1
0.4%
chlor 1
0.4%
chlorphenamine 1
0.4%
chlorpheniramine 1
0.4%
chlorpheramine 1
0.4%
ciprofloxacin 1
0.4%
coartem 1
0.4%
cotri 1
0.4%
depot provera 1
0.4%
diclo 2
0.9%
diclo fenac 1
0.4%
diclo inj 1
0.4%
digoxine 1
0.4%
ery 500 1
0.4%
erythromicine 1
0.4%
erythromycine 1
0.4%
erytromicine 2
0.9%
etythromycine 1
0.4%
furosemide 1
0.4%
furosomyde injectable 1
0.4%
gant 1
0.4%
hydro 1
0.4%
hydroxicine d aluminum 1
0.4%
hyoscine butylbromide 1
0.4%
ibuprofane 1
0.4%
ibuprofen 1
0.4%
jadel 2
0.9%
mebendazole 2
0.9%
metro 1
0.4%
metrochloropramide 1
0.4%
miconazole pommade 1
0.4%
multi 1
0.4%
nifidipine 1
0.4%
novartis 1
0.4%
nystatine 1
0.4%
omeprazole gelules 1
0.4%
oo 1
0.4%
para 5
2.2%
para cp 3
1.3%
paracetamol 12
5.4%
paracetamol 500mg 1
0.4%
paracetamol comp 2
0.9%
phloro 2
0.9%
phloro cp 1
0.4%
phloroglicenol 1
0.4%
phloroglicinol 1
0.4%
phloroglucinol 10
4.5%
phloroglucinol inj 1
0.4%
phloroglucinole inj 1
0.4%
phloroglucinon 1
0.4%
phoroglucinol 1
0.4%
phoroglucinol cp 1
0.4%
ploroglucinol 1
0.4%
profundin 1
0.4%
provera 2
0.9%
quinine 4
1.8%
quinine 300 2
0.9%
vitamine c 1
0.4%
xylocaine 1
0.4%
zinnia 1
0.4%
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.
Back to Catalog
The World Bank Working for a World Free of Poverty
  • IBRD IDA IFC MIGA ICSID

© The World Bank Group, All Rights Reserved.

This site uses cookies to optimize functionality and give you the best possible experience. If you continue to navigate this website beyond this page, cookies will be placed on your browser. To learn more about cookies, click here.